Department of Chemistry "Ugo Schiff", University of Florence , Sesto Fiorentino , Italy.
Center for Colloid and Surface Science (CSGI), University of Florence , Sesto Fiorentino , Italy.
J Enzyme Inhib Med Chem. 2019 Dec;34(1):1711-1715. doi: 10.1080/14756366.2019.1667342.
α-Synuclein (α-syn), a disordered cytoplasmatic protein, plays a fundamental role in the pathogenesis of Parkinson's disease (PD). Here, we have shown, using photophysical measurements, that addition of FKBP12 to α-syn solutions, dramatically accelerates protein aggregation, leading to an explosion of dendritic structures revealed by fluorescence and phase-contrast microscopy. We have further demonstrated that this aberrant α-syn aggregation can be blocked using a recently discovered non-immunosuppressive synthetic inhibitor of FKBP12, ElteN378. The role of FKBP12 and of ElteN378 in the α-syn aggregation mechanism has been elucidated using molecular dynamics simulations based on an effective coarse-grained model. The reported data not only reveal a new potent synthetic drug as a candidate for early stage treatment of α-syn dependent neurodegenerations but also pave the way to a deeper understanding of the mechanism of action of FKBP12 on α-syn oligomeric aggregation, a topic which is still controversial.
α-突触核蛋白(α-syn)是一种无序的细胞质蛋白,在帕金森病(PD)的发病机制中起着至关重要的作用。在这里,我们使用光物理测量表明,FKBP12 的加入极大地加速了 α-syn 溶液中的蛋白质聚集,导致荧光和相差显微镜揭示的树突状结构的爆炸。我们进一步证明,这种异常的 α-syn 聚集可以使用最近发现的 FKBP12 的非免疫抑制性合成抑制剂 ElteN378 来阻断。使用基于有效粗粒度模型的分子动力学模拟阐明了 FKBP12 和 ElteN378 在 α-syn 聚集机制中的作用。报道的数据不仅揭示了一种新的有效合成药物作为治疗依赖α-syn 的神经退行性疾病的早期阶段的候选药物,而且为深入了解 FKBP12 对 α-syn 寡聚聚集的作用机制铺平了道路,这个话题仍存在争议。